Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIANGLE phase 3 trial of ibrutinib and autologous stem cell transplantation in previously untreated mantle cell lymphoma
MOH_2018-08-07_002486Phase 3Not yet recruiting
- Sponsor
- LMU Klinikum
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ibrutinib in mantle cell lymphoma (MCL) (3 arms), sponsored by LMU Klinikum. Planned start May 2018; status: not yet recruiting.
02
Drugs
ibrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on MOH_2018-08-07_002486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-08-07_002486.